Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/a-1911-3755
Osteogenesis Imperfecta: Multidisciplinary and Goal-Centered Care
![](https://www.thieme-connect.de/media/ajpr/202203/lookinside/thumbnails/10-1055-a-1911-3755_22mar0045-1.jpg)
Abstract
We describe a case of osteogenesis imperfecta (OI) in a late preterm female of 35-week gestation. The mother did have a history of substance abuse, poor prenatal care, and hypertension. On the day of delivery, an ultrasound revealed skeletal dysplasia and breech with nonreassuring fetal tracing, leading to an emergency cesarean. The clinical exam was concerning for OI, and postnatal care was focused on optimizing respiratory status and minimizing pain and discomfort during routine care. Genetics, endocrine, orthopaedics, and palliative care were all involved to diagnose and educate the family. Support and education were needed for bedside staff to minimize angst at performing routine care, given the high risk of fractures. While initially stable on minimal oxygen, once the diagnosis of type III OI was made, a progressively deforming condition with respiratory status decompensation, the family wished to minimize suffering, limited aggressive medical care, and focused on comfort. The infant eventually died from respiratory failure in the neonatal intensive care unit. We present this case to demonstrate the need for an interdisciplinary team approach to support both family and staff in cases of OI.
Publication History
Received: 18 March 2022
Accepted: 06 July 2022
Accepted Manuscript online:
28 July 2022
Article published online:
30 September 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Steiner RD, Basel D. COL1A1/2 osteogenesis omperfecta. In: Adam MP, Ardinger HH, Pagon RA. et al., eds. GeneReviews((R)). Seattle, WA: 1993
- 2 Yimgang DP, Brizola E, Shapiro JR. Health outcomes of neonates with osteogenesis imperfecta: a cross-sectional study. J Matern Fetal Neonatal Med 2016; 29 (23) 3889-3893
- 3 Sinikumpu JJ, Ojaniemi M, Lehenkari P, Serlo W. Severe osteogenesis imperfecta Type-III and its challenging treatment in newborn and preschool children. A systematic review. Injury 2015; 46 (08) 1440-1446
- 4 Starr SR, Roberts TT, Fischer PR. Osteogenesis imperfecta: primary care. Pediatr Rev 2010; 31 (08) e54-e64
- 5 Womack J. Osteogenesis imperfecta types I-XI: implications for the neonatal nurse. Adv Neonatal Care 2014; 14 (05) 309-315 , quiz 316–317
- 6 Bellur S, Jain M, Cuthbertson D. et al; Members of the BBD Consortium. Cesarean delivery is not associated with decreased at-birth fracture rates in osteogenesis imperfecta. Genet Med 2016; 18 (06) 570-576
- 7 Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tatò L. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 2006; 149 (02) 174-179
- 8 Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2016; 10: CD005088
- 9 Eto S, Hada S, Fukuhara R, Nishimura G, Takagi M. Cyclic intravenous pamidronate in a very low-birthweight infant with osteogenesis imperfecta. Pediatr Int 2018; 60 (05) 485-486
- 10 McCarthy EA, Raggio CL, Hossack MD. et al. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res 2002; 52 (05) 660-670
- 11 Ralston SH, Gaston MS. Management of osteogenesis imperfecta. Front Endocrinol (Lausanne) 2020; 10: 924